|
Keyhole Limpet Hemocyanin Compared With Doxorubicin in Treating Patients With Bladder Cancer Clinical Trials References presented on Clinical Trials Search isn't meant to be a substitute for proven healthcare advice, trips or professional assistance using a genuine physician. We are not docs. Always confer with your physician about Keyhole Limpet Hemocyanin Compared With Doxorubicin in Treating Patients With Bladder Cancer conditions. Clinical Trials Search.org is a site devoted to listing clinical research studies in human subjects. Keyhole Limpet Hemocyanin Compared With Doxorubicin in Treating Patients With Bladder Cancer Clinical research trials and Keyhole Limpet Hemocyanin Compared With Doxorubicin in Treating Patients With Bladder Cancer healthcare trials happen in hundreds of localities throughout the United States of America. A clinical trial or clinical study is a research project with human volunteer subjects. Clinical drug trials and pharmaceutical clinical trials usually evaluate the potency of new drugs. The propose of the studies / projects is to answer particular human health questions. Clinical trials are a popular way for mDs, government agencies, and private sector companies to detect cures for all sorts of conditions, such as Keyhole Limpet Hemocyanin Compared With Doxorubicin in Treating Patients With Bladder Cancer. Keyhole Limpet Hemocyanin Compared With Doxorubicin in Treating Patients With Bladder Cancer Clinical Trials and other clinical trials allow volunteers to acquire healthcare treatment choices before they are available to the general public. Some times the subjects recieve professional assistance for free, and every now and again they are compensated for their time. Sometimes there is a cost for a Keyhole Limpet Hemocyanin Compared With Doxorubicin in Treating Patients With Bladder Cancer clinical trial. Subjects frequently obtain the most expert healthcare possible for their Keyhole Limpet Hemocyanin Compared With Doxorubicin in Treating Patients With Bladder Cancer condition. Risks are a reality, nevertheless, and can include more or frequent doctor trips, medical risks (possibly life-threatening), and/or the treatment being uneffective. Trials are federally governed with stern guidelines to protect clinical trials patients.
|
|
|
|
|
|
|
Home > "K" Clinical Trials Conditions > Keyhole Limpet Hemocyanin Compared With Doxorubicin in Treating Patients With Bladder Cancer  Keyhole Limpet Hemocyanin Compared With Doxorubicin in Treating Patients With Bladder Cancer
Keyhole Limpet Hemocyanin Compared With Doxorubicin in Treating Patients With Bladder Cancer
For Condition: stage 0 bladder cancer,recurrent bladder cancer
Status: Suspended
Sponsor(s): Intracel ,
Synopsis: RATIONALE: Biological therapies use different ways to stimulate the immune system and stop cancer cells from growing. Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. It is not yet known whether keyhole limpet hemocyanin is more effective than doxorubicin for bladder cancer. PURPOSE: Randomized phase III trial to compare the effectiveness of keyhole limpet hemocyanin with that of doxorubicin in treating patients who have bladder cancer that has not responded to BCG or in those patients who cannot tolerate BCG.
Details: OBJECTIVES: - Compare the efficacy of BCI-ImmuneActivator™ (keyhole limpet hemocyanin) versus doxorubicin in BCG refractory or intolerant patients with carcinoma in situ with or without resected superficial papillary bladder cancer. - Compare the toxicity and safety of these treatments in these patients. OUTLINE: This is a randomized, multicenter study. Patients are stratified according to participating center and prior BCG response (refractory vs intolerant). Patients are randomized to 1 of 2 treatment arms. - Arm I: Patients receive a sensitizing dose of keyhole limpet hemocyanin (KLH) intradermally at week -2 followed by induction KLH IV once weekly at weeks 1-6. Patients with partial or no response receive IV KLH reinduction therapy once weekly at weeks 13-18. Patients with complete response receive IV KLH maintenance therapy monthly at weeks 13, 17, and 21, and then at months 6-12. - Arm II: Patients receive doxorubicin IV once weekly at weeks 1-6. Patients with complete response receive maintenance therapy comprising doxorubicin IV at weeks 13, 17, and 21 and months 6-12. Treatment continues in the absence of disease progression or unacceptable toxicity. Patients are followed every 3 months for 1.5 years, and then every 6 months for 1 year. (Patient total participation in this study may last as long as 42 months.) PROJECTED ACCRUAL: A total of 150 patients (75 per treatment arm) will be accrued for this study.
Eligibility:
Study Type: Interventional, Treatment
Minimum Age/Maximum Age: 18 Years/
Genders: Both
Protocol Entry Criteria: DISEASE CHARACTERISTICS: - Histologically or cytologically confirmed carcinoma in situ of the bladder with or without resected superficial papillary tumor - Biopsy within 3 months of study with or without positive urinary cytology within 6 weeks of study - Cystoscopy within 3 months of study - Negative imaging study of the ureters and kidneys within 6 months of study - BCG refractory disease - Received and failed at least 1 prior induction course consisting of BCG weekly for 6 weeks OR - BCG intolerant - Unable to receive an adequate course of intravesical BCG due to extreme toxicity - Opted against or medically contraindicated to cystectomy PATIENT CHARACTERISTICS: Age - 18 and over Performance status - ECOG 0-2 OR - Karnofsky 60-100% Life expectancy - Not specified Hematopoietic - WBC greater than 4,000/mm^3 - Platelet count greater than 100,000/mm^3 - Hemoglobin greater than 11 g/dL Hepatic - Bilirubin normal - SGOT/SGPT normal Renal - Creatinine no greater than 1.5 times upper limit of normal Cardiovascular - No severe cardiovascular disease Other - No other severe disease - No other malignancy within the past 5 years except basal or squamous cell skin cancer or noninvasive cancer of the cervix - No evidence of autoimmune disease, known immune deficiency, or immunosuppression - Not pregnant or nursing - Negative pregnancy test - Fertile patients must use effective contraception PRIOR CONCURRENT THERAPY: Biologic therapy - See Disease Characteristics - No prior keyhole limpet hemocyanin immune activator Chemotherapy - No prior doxorubicin - At least 3 months since prior mitomycin - No other concurrent chemotherapy Endocrine therapy - No concurrent steroids Radiotherapy - At least 4 months since prior radiotherapy Surgery - See Disease Characteristics Other - At least 4 weeks since prior intravesical therapy - At least 3 months since prior investigational agents - No concurrent cytotoxic immunosuppressive agents
Total Enrollment:
Location and Contact Information:
Overall Study Official:
MichaelHanna Jr., Study Chair, Intracel
Intracel Resources, LLC
Frederick, Maryland, 21701
United States
Additional Information:
Study ID Numbers: CDR0000068047; INTRACEL-BCI-9804-04
Study Start Date:
Record last reviewed: March 2004
Additional information available at: clinicaltrials.gov
Clinicaltrials.gov Reference link: NCT00006034
Other Stage 0 Bladder Cancer Studies:
1. Combination Chemotherapy Plus Filgrastim in Treating Patients With Locally Recurrent or Advanced Urothelium Cancer
2. AD 32 Alone or With BCG Following Surgery in Treating Patients With Newly Diagnosed or Recurrent Superficial Bladder Cancer
3. BCG Plus Interferon alfa 2b in Treating Patients With Bladder Cancer
4. Tipifarnib in Treating Patients With Recurrent Bladder Cancer
5. Fluorouracil in Treating Patients With Recurrent or Metastatic Bladder Cancer
Related Studies:
Other stage 0 bladder cancer Clinical Trials
Other Maryland Clinical Trials
Other Frederick Clinical Trials
Keyhole Limpet Hemocyanin Compared With Doxorubicin in Treating Patients With Bladder Cancer
|
|
|
|
|
|
|
|
